Gene-editing specialist Seamless Therapeutics has attracted its first major pharma partner, Eli Lilly, with a $1.12 billion alliance that will seek out therapies for hearing loss.

Materialise NV (NASDAQ:MTLS) presented its fourth quarter and full-year 2025 financial results on February 19, 2026, revealing a 6.8% year-over-year revenue increase to €70.2 million in Q4, despite ...

Jan 28 (Reuters) - U.S. drugmaker Eli Lilly (LLY.N), opens new tab signed an agreement worth up to $1.12 billion with Seamless Therapeutics, the Germany-based startup said on Wednesday, to develop and ...

Eli Lilly is continuing a run of dealmaking to strengthen its genetic medicine offering by penning a pact with gene editing company Seamless Therapeutics. This morning’s deal with Seamless centers on ...

Eli Lilly plans to expand its hearing loss therapy pipeline by collaborating with Seamless Therapeutics to apply the company’s next-generation gene-editing approach, based on programmable recombinases ...

It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it happened in Materialise NV's (NASDAQ:MTLS) case, it's fantastic news for shareholders.

Forward-looking: While examining polymer nanostructures with a scanning electron microscope, researchers at Stanford University discovered that the new material can easily change its color and surface ...

Some octopuses have incredible camouflaging abilities. Victor Micallef via Wikimedia Commons under CC BY-SA 4.0 Octopuses and cuttlefish are sneaky sea creatures. To hide from predators and surprise ...

Octopus and cuttlefish are masters of disguise. Many species can rapidly change both the color and the texture of their skin – an ability that scientists have long sought to replicate with synthetic ...

Researchers have developed a flexible material that can quickly change its surface texture and colors, offering potential applications in camouflage, art, robotics, and even nanoscale bioengineering. ...

Materialise (MTLS) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces ...